Fusion Pharmaceuticals is a clinical-stage oncology company that develops radiopharmaceuticals as precision medicines using its Targeted Alpha Therapies platform and Fast-Clear linker technology. Its lead product candidate, FPI-1434, is in Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors. Fusion Pharmaceuticals has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for cancer treatment.